Compare ORI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORI | TGTX |
|---|---|---|
| Founded | 1923 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 8.5B |
| IPO Year | 1994 | 2008 |
| Metric | ORI | TGTX |
|---|---|---|
| Price | $41.08 | $55.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $43.50 | ★ $49.80 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 9.47% | N/A |
| EPS Growth | 14.81 | ★ 1746.67 |
| EPS | ★ 1.32 | 0.12 |
| Revenue | ★ $9,136,300,000.00 | $2,785,000.00 |
| Revenue This Year | $7.07 | $49.08 |
| Revenue Next Year | $6.86 | $26.69 |
| P/E Ratio | ★ $31.52 | $439.00 |
| Revenue Growth | ★ 10.99 | N/A |
| 52 Week Low | $35.60 | $25.37 |
| 52 Week High | $46.76 | $59.30 |
| Indicator | ORI | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 46.45 |
| Support Level | $40.49 | $51.15 |
| Resistance Level | $43.36 | $58.34 |
| Average True Range (ATR) | 0.74 | 2.29 |
| MACD | -0.13 | -1.00 |
| Stochastic Oscillator | 23.39 | 6.05 |
Old Republic International Corp is engaged in the business of insurance underwriting and related services. The company operates in two segments: Specialty Insurance and Title Insurance. The insurance provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others. The company generates the majority of its revenue from Specialty Insurance. The Specialty Insurance provides property and liability insurance principally to commercial clients.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.